ANTX Quote Trading Chart AN2 Therapeutics Inc.

$ Last:

-1.27% Change Percent:

$57.76 Open:

$56.86 Previous Close:

$58.14 High:

$56.86 Low:

315,708 Volume:

12/31/1969 07:00:00 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2018-04-30	57.76	56.86	58.14	56.86	315,708
2018-04-27	56.92	57.59	57.86	56.92	4,322,357
2018-04-26	58.27	57.22	59.10	57.00	4,430,352
2018-04-25	55.00	57.61	57.71	53.8601	1,725,049
2018-04-24	54.85	54.31	54.99	53.95	3,790,173
2018-04-23	54.50	54.5654	55.069	54.43	303,300
2018-04-20	55.00	54.51	55.31	54.33	18,693
2018-04-19	55.54	54.9354	55.67	54.7454	10,772
2018-04-18	55.40	55.65	55.77	55.3298	554,234
2018-04-17	54.64	55.36	55.8199	54.64	3,705,905
2018-04-16	53.78	54.34	54.58	53.77	496,156
2018-04-13	53.61	53.50	53.86	53.46	370,962
2018-04-12	53.60	53.19	53.78	53.12	2,404,746
2018-04-11	54.10	53.75	54.10	53.74	4,488
2018-04-10	54.83	54.82	54.91	54.70	17,504
2018-04-09	55.37	54.37	55.37	54.31	121,751
2018-04-06	55.81	54.92	56.09	54.41	64,619
2018-04-05	55.96	56.36	56.44	55.6795	127,237
2018-04-04	55.30	55.85	55.85	54.85	22,219

Stock Information

AN2 Therapeutics Inc. Company Name:

ANTX Stock Symbol:

NYSE Market:

Get ANTX Alerts

News, Short Squeeze, Breakout and More Instantly...

ANTX - AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

Enrolling U.S. Patients in the EBO-301 Pivotal Phase 2/3 Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Topline Results from Phase 2 Part of Trial Expected in Mid-2023 Completed Enrollment in Phase 1 PK/Safety Study of Epetraborole in Healthy Volun...
ANTX - AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an initial focus on treatment-refractory MAC lung disease Phase 2/3 pivotal trial expected to support regulatory approv...
ANTX - AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing Epetraborole Clinical Program with Enrollment for Pivotal Phase 2/3 Trial in Treatment-Refractory MAC Lung Disease Expected to Beg...